Crystalline forms of therapeutic compounds and uses thereof

• US 9,890,173 B2
• Filed: 05/24/2017
• Issued: 02/13/2018
• Est. Priority Date: 11/01/2013
• Status: Active Grant

• Current Assignee: Kala Bio, Inc.
• Original Assignee: Kala Pharmaceuticals, Inc.
• Inventors: Enlow, Elizabeth, Nguyen, Minh Ngoc, Ong, Winston Z.
• Primary Examiner(s): Ward, Paul V
• Application Number:
  US15/604,080
• Publication Number:
  US 20170260193A1
• Time in Patent Office: 265 Days
• CPC Class Codes: A61K 31/517 ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/5031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/5146 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
• CPC Class Codes: C07B 2200/13 Crystalline forms, e.g. polymorphs
• CPC Class Codes: C07D 491/107 with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

Described herein is certain crystalline forms of Compound 5, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.

Claims

1. A method of inhibiting growth factor signaling comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline form of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one comprising:

(i) crystalline Form II having an X-ray powder diffraction (XRPD) pattern with peaks at about 8.44, 10.57, 14.92, 17.22, 21.26 and 22.42±

0.2 degrees two theta, or 10.47, 8.36, 5.93, 5.15, 4.18 and 3.96±

0.2 Å

in d-spacing;

or

(ii) crystalline Form III having an XRPD pattern with peaks at about 9.60, 10.45, 19.30, 19.71, 21.84, and 23.42±

0.2 degrees two theta or 9.21, 8.46, 4.60, 4.50, 4.07 and 3.80±

0.2 Å

in d-spacing.

2. The method of claim 1, wherein crystalline Form II has the XRPD pattern as shown in FIG. 2.

3. The method of claim 1, wherein crystalline Form III has the XRPD pattern as shown in FIG. 3.

4. The method of claim 1, wherein the crystalline form is administered topically, by injection, to the eye, orally, or by inhalation.

5. The method of claim 1, wherein the inhibition of growth factor signaling treats an ocular disease.

6. The method of claim 5, wherein the ocular disease is retinopathy, age-related macular degeneration, corneal neovascularization, diabetic macular edema, or retinal vein occlusion.

7. The method of claim 1, wherein the inhibition of growth factor signaling treats a proliferative disorder.

8. The method of claim 7, wherein the proliferative disorder is a cancer.

9. A method of inhibiting growth factor signaling comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising:

a plurality of coated particles, comprising;

a core particle comprising a crystalline form of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one, wherein the crystalline form constitutes at least about 80 wt % of the core particle; and

a coating comprising one or more surface-altering agents surrounding the core particle;

wherein the crystalline form is;

(i) crystalline Form II having an X-ray powder diffraction (XRPD) pattern with peaks at about 8.44, 10.57, 14.92, 17.22, 21.26 and 22.42±

0.2 degrees two theta, or 10.47, 8.36, 5.93, 5.15, 4.18 and 3.96±

0.2 Å

in d-spacing;

or

(ii) crystalline Form III having an XRPD pattern with peaks at about 9.60, 10.45, 19.30, 19.71, 21.84, and 23.42±

0.2 degrees two theta or 9.21, 8.46, 4.60, 4.50, 4.07 and 3.80±

0.2 Å

in d-spacing.

10. The method of claim 9, wherein the one or more surface-altering agents comprises a triblock copolymer comprising a hydrophilic block-hydrophobic block-hydrophilic block configuration, wherein the hydrophobic block has a molecular weight of at least about 2 kDa, and the hydrophilic blocks constitute at least about 15 wt % of the triblock copolymer.

11. The method of claim 9, wherein the crystalline form is administered topically, by injection, to the eye, orally, or by inhalation.

12. The method of claim 9, wherein the inhibition of growth factor signaling treats an ocular disease.

13. The method of claim 12, wherein the ocular disease is retinopathy, age-related macular degeneration, corneal neovascularization, diabetic macular edema, or retinal vein occlusion.

14. The method of claim 9, wherein the inhibition of growth factor signaling treats a proliferative disorder.

15. The method of claim 14, wherein the proliferative disorder is a cancer.